MG
CASI

Michael Gelband’s CASI Pharmaceuticals CASI Stock Holding History

Michael Gelband’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,604
Closed -$71K – 2154
2021
Q2 		$71K Buy
+4,604
New +$77.4K ﹤0.01% 2193

Other funds holding CASI

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
IACGFIA
IDG-Accel China Growth Fund III Associates Hong Kong $31.2M AUM 2.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Michael Gelband's CASI Position: Q3 2021 in Review

Michael Gelband sold out of CASI Pharmaceuticals (CASI) in Q3 2021, closing a stake of 4,604 shares — an estimated $71K sold.

Michael Gelband first reported a position in CASI in Q2 2021 and held it in 1 quarter. The position peaked at $71K in Q2 2021. 58 funds tracked by Wall St. Rank hold CASI as of Q3 2021.

  • Michael Gelband reported no remaining CASI Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Michael Gelband sold 4,604 CASI Pharmaceuticals shares in Q3 2021, an estimated $71K.
  • Michael Gelband first reported a position in CASI Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Michael Gelband's CASI Pharmaceuticals position peaked at $71K in Q2 2021.
  • 58 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q3 2021.

Based on ExodusPoint Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.